Alpha Score of 36 reflects weak overall profile with poor momentum, moderate value, weak quality, moderate sentiment.
Abbott Laboratories (ABT) closed the session with an Alpha Score of 50, reflecting a neutral market posture across all core metrics. The stock currently trades at a price-to-earnings ratio consistent with its historical healthcare sector averages, suggesting that investors are pricing in stable, predictable growth rather than aggressive expansion. Momentum indicators remain flat, as the share price continues to oscillate within its established 52-week range without testing significant resistance or support levels. The quality sub-score remains balanced, supported by consistent cash flow generation, while sentiment metrics show no meaningful deviation from baseline expectations. With growth rates hovering near industry norms, the market appears to be waiting for a catalyst to shift the stock out of its current equilibrium. The lack of volatility in the sentiment and momentum components highlights a period of consolidation for the company. Investors should monitor upcoming quarterly earnings reports and potential shifts in medical device demand to identify any emerging trends that could influence the current neutral positioning of the stock throughout the remainder of the quarter.
Abbott Laboratories (ABT) closed the session with a neutral market profile, reflecting a lack of significant directional movement. The stock currently holds an Alpha Score of 50, indicating a balanced distribution across its underlying sub-scores. Momentum, value, quality, and sentiment metrics remain stagnant, suggesting that investors are currently in a holding pattern regarding the healthcare giant. The firm’s valuation, measured by its current P/E ratio, sits in line with historical averages for the sector, while year-over-year growth rates show moderate stability without providing a clear catalyst for a breakout or a correction. Positioned near the midpoint of its 52-week range, ABT continues to trade within a well-defined channel. The absence of volatility in the sentiment sub-score reinforces the view that the market is awaiting fresh fundamental data to shift the current equilibrium. Without significant deviations in operational performance or broader sector shifts, the stock remains anchored to its present valuation levels. Market participants should continue to monitor upcoming quarterly earnings reports and management guidance for potential shifts in growth trajectory or margin expansion throughout the remainder of the fiscal quarter.
On March 23, 2026, Abbott Laboratories finalized its acquisition of Exact Sciences Corporation. The transaction was executed pursuant to the Agreement and Plan of Merger originally dated November 19, 2025. Under the terms of the agreement, a wholly owned subsidiary of Abbott, Badger Merger Sub I, Inc., merged with and into Exact Sciences. As a result of the merger, Exact Sciences now operates as a direct, wholly owned subsidiary of Abbott Laboratories. Shareholders of Exact Sciences common stock received $105.00 in cash for each share held immediately prior to the effective time of the merger, excluding certain shares as defined in the agreement. The filing confirms the completion of the merger and incorporates the original merger agreement and a press release regarding the closing as exhibits.
On March 9, 2026, Abbott Laboratories completed a public offering of $20 billion in aggregate principal amount of senior notes. The issuance consists of eight series of notes with varying maturities, ranging from floating rate notes due in 2029 to fixed-rate notes maturing as late as 2066. The offering was conducted pursuant to a pricing agreement dated February 23, 2026, with underwriters including Morgan Stanley, Barclays, BofA Securities, and J.P. Morgan Securities. Abbott intends to use the net proceeds from this offering, alongside cash on hand and potential additional borrowings, to finance its previously announced acquisition of Exact Sciences Corporation. The funds are earmarked for the merger consideration, the repayment of certain Exact Sciences indebtedness, transaction-related fees, and general corporate purposes. The notes include a special mandatory redemption provision. If the acquisition of Exact Sciences is not consummated by the specified "End Date" (generally February 17, 2027, or a later agreed-upon date) or if Abbott notifies the trustee that it will not pursue the acquisition, the company is required to redeem the outstanding notes at 101% of their aggregate principal amount, plus accrued and unpaid interest.
| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Mar 2, 26 | Shroff Eric | Senior Vice President | SELL | 709 | $82K |
| Mar 2, 26 | Salvadori Daniel Gesua Sive | EVP AND GROUP PRESIDENT | SELL | 885 | $102K |
| Mar 2, 26 | Morrone Louis H. | EXECUTIVE VICE PRESIDENT | SELL | 1.1K | $132K |
| Fund | Shares Held | Position Value | Action (latest Q) |
|---|---|---|---|
| Citadel Ken Griffin | 5.19M | $649.93M | NEW |
| D.E. Shaw David Shaw | 2.04M | $255.68M | NEW |
| Renaissance Technologies Jim Simons (founder) | 558K | $69.92M | NEW |
| Point72 Steve Cohen | 412K | $51.67M | NEW |
| Marshall Wace | 59K | $7.34M | NEW |
| Blackstone | 23K | $2.86M | NEW |
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad portfolio of health care products worldwide. It operates across four key segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, addressing needs from chronic disease management to acute diagnostics. The company offers generic pharmaceuticals treating conditions such as pancreatic exocrine insufficiency, irritable bowel syndrome, dyslipidemia, hypertension, hypothyroidism, pain, fever, inflammation, and migraine, alongside anti-infectives, influenza vaccines, and gastrointestinal regulators. Notable products include cardiovascular devices like pacemakers and stents, diabetes management tools such as continuous glucose monitors, pediatric and adult nutritional formulas, and advanced diagnostic equipment like immunoassays and point-of-care testing kits. With approximately 114,000 employees and a history dating back to 1888, Abbott Laboratories generates the majority of its sales outside the United States, playing a pivotal role in advancing medical innovation, improving patient outcomes, and supporting global health initiatives through its extensive reach in consumer, institutional, and professional markets.
Earnings calendar coming soon. Subscribe to get notified when ABT reports next.
Get earnings alerts →